CSPC Innovation Pharmaceutical Co Ltd Class A Total Liabilities
CSPC Innovation Pharmaceutical Co Ltd Class A total liabilities. Based on the latest financial reports, CSPC Innovation Pharmaceutical Co Ltd Class A (300765) has total liabilities worth CN¥3.54 Billion CNY (≈ $517.96 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 300765 asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of CSPC Innovation Pharmaceutical Co Ltd Class A (2014–2025)
Total liabilities of CSPC Innovation Pharmaceutical Co Ltd Class A from 2014 to 2025. This chart illustrates how CSPC Innovation Pharmaceutical Co Ltd Class A's total liabilities have evolved over time, based on quarterly financial data.
CSPC Innovation Pharmaceutical Co Ltd Class A Competitors by Total Liabilities
The table below lists competitors of CSPC Innovation Pharmaceutical Co Ltd Class A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
OR Royalties Inc.
TO:OR
|
Canada | CA$371.92 Million |
|
Madison Square Garden Sports Corp
NYSE:MSGS
|
USA | $1.80 Billion |
|
Magyar Telekom Távközlési Nyilvánosan Müködö Részvénytársaság
F:MGYB
|
Germany | €640.28 Billion |
|
Indian Overseas Bank
NSE:IOB
|
India | Rs4.12 Trillion |
|
PrairieSky Royalty Ltd
TO:PSK
|
Canada | CA$552.10 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $154.41 Million |
|
China Aerospace Times Electronics Co Ltd
SHG:600879
|
China | CN¥23.89 Billion |
Liability Composition Analysis (2014–2025)
This chart breaks down CSPC Innovation Pharmaceutical Co Ltd Class A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 300765 asset base.
Liquidity & Leverage Metrics
CSPC Innovation Pharmaceutical Co Ltd Class A Total Liabilities Ratios Explained
CSPC Innovation Pharmaceutical Co Ltd Class A total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.37 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.57 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CSPC Innovation Pharmaceutical Co Ltd Class A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CSPC Innovation Pharmaceutical Co Ltd Class A (2014–2025)
The table below shows the annual total liabilities of CSPC Innovation Pharmaceutical Co Ltd Class A from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥3.48 Billion ≈ $509.39 Million |
+128.09% |
| 2024-12-31 | CN¥1.53 Billion ≈ $223.33 Million |
-23.27% |
| 2023-12-31 | CN¥1.99 Billion ≈ $291.04 Million |
+210.85% |
| 2022-12-31 | CN¥639.84 Million ≈ $93.63 Million |
+44.25% |
| 2021-12-31 | CN¥443.58 Million ≈ $64.91 Million |
+64.50% |
| 2020-12-31 | CN¥269.65 Million ≈ $39.46 Million |
-38.30% |
| 2019-12-31 | CN¥437.06 Million ≈ $63.96 Million |
+11.65% |
| 2018-12-31 | CN¥391.45 Million ≈ $57.28 Million |
+8.09% |
| 2017-12-31 | CN¥362.16 Million ≈ $53.00 Million |
-8.70% |
| 2016-12-31 | CN¥396.66 Million ≈ $58.04 Million |
+20.13% |
| 2015-12-31 | CN¥330.20 Million ≈ $48.32 Million |
+12.06% |
| 2014-12-31 | CN¥294.66 Million ≈ $43.12 Million |
-- |
About CSPC Innovation Pharmaceutical Co Ltd Class A
CSPC Innovation Pharmaceutical Co., Ltd. engages in the research and development, production, and sales of biopharmaceuticals, functional foods, and raw materials in China and internationally. The company offers functional raw ingredients, including caffeine, acarbose, anhydrous glucose, theophylline, aminophylline, dyphylline, theobromine, pentoxifylline, and doxofylline; and health food product… Read more